- Interim data on RVU120 in patients with high-risk AML or MDS, and SEL24 (MEN1703) in patients with IDH1/2 mutation AML will be announced at the 2022 European Hematology Association Congress ( WASH)
KRAKOW, Poland, May 18, 2022 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focused on novel small molecule therapies that target emerging targets in oncology, today reported results financial statements for the first quarter of 2022 and provided a company update.
“As we prepare for several important milestones in our clinical-stage programs in 2022, we continue to execute on our mission to develop innovative new medicines that will improve the lives of cancer patients,” said Pawel Przewiezlikowski, CEO of Ryvu. Therapeutics. “We look forward to presenting preclinical and clinical data on the novel CDK8/19 inhibitor, RVU120, and on SEL24 (MEN1703) at the upcoming meeting of the European Hematology Association (EHA) and American Society. of Clinical Oncology. the clinical readouts will provide Ryvu with valuable data-driven insights that will help us optimize the clinical development strategy for our key pipeline assets. »
FIRST QUARTER 2021 AND RECENT HIGHLIGHTS
Poster presentations at the American Association for Cancer Research (AACR) Annual Meeting: Data were presented from the ongoing RVU120 trial in patients with metastatic or advanced relapsed/refractory solid tumor and in vitro and live data demonstrating the efficacy of RVU120 against hormone-independent breast cancer. In addition, a novel cooperative PRMT5 inhibitor of MTA as a targeted therapeutic for MTAP-deleted cancer was presented.
The meeting of Hendrik NogaiMD as Chief Medical Officer: Dr. Nogai brings 10 years of practice in the treatment of hematologic and solid malignancies and 17 years of clinical development industry experience. Dr. Nogai leads the medical, clinical and regulatory functions to accelerate the development of the company’s pipeline.
Next clinical and corporate steps
RVU120
Phase Clinical Update 1b dose-escalation study of RVU120 in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) and preclinical data describing in vitro and live Effects of RVU120 treatment in DNMT3a and NPM1-mutated AML patient-derived cells (PDCs) will be announced as poster presentations at the 2022 European Hematology Association Congress.
Update of the Phase 1/2 trial of RVU120 in patients with metastatic or advanced relapsed/refractory (r/r) solid tumors to be announced as an abstract book entry at the next annual meeting American Society of Clinical Oncology (ASCO) 2022: Phase 1/2 clinical trial is an open-label, single-agent study evaluating the safety, tolerability, and preliminary efficacy of RVU120 in dose-escalating cohorts in patients with metastatic or advanced r/r solid tumors.
SEL24 (MEN1703)
Program update for the Phase 1/2 DIAMOND-01 trial of SEL24 (MEN1703), a first-in-class dual PIM/FLT3 kinase inhibitor in patients with acute myeloid leukemia (AML) ) with IDH1/2 mutation will be presented at ASCO by Ryvu partner Menarini Group. The Phase 1/2 DIAMOND-01 trial is evaluating the clinical activity of SEL24 (MEN1703) monotherapy in patients with AML.
Interim data from the Phase 1/2 study of SEL24 (MEN1703) in patients with IDH1/2 mutation AML will also be presented by Menarini at the 2022 European Hematology Association Congress.
Synthetic Lethality
Continuous hit-to-lead optimization of the most advanced program PRMT5 with live POC expected in H2 2022
Identification of new targets
First Quarter 2022 Financial Update
Treasury – Total cash and cash equivalents $15.5M at the end of the first quarter of 2022, compared to $20.5M at the end of the fourth quarter of 2021.
operating costs, excluding the non-cash cost of the evaluation of the incentive program ($2 million), for the quarter ended March 31, 2022amounted to $6.2M and related primarily to research and development expenses, while operating costs without incentive program for the quarter ended March 31, 2021amounted to $5.8M.
Net loss attributable to common shareholders – The net loss attributable to common shareholders excluding the non-cash cost of the incentive program evaluation was $4.4M for the quarter ended March 31, 2022compared to a net loss of $3.6M for the quarter ended March 31, 2021.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that target emerging targets in oncology. The internally discovered pipeline candidates utilize a variety of therapeutic mechanisms driven by new insights into cancer biology, including small molecule kinase-directed, synthetic lethality, and immuno-oncology targets.
Ryvu’s most advanced programs are RVU120 – a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic, and phase I/II for the treatment of metastatic or advanced solid tumors r/r and SEL24 (MEN1703) – dual PIM/FLT3 kinase inhibitor licensed from the Menarini group, currently in phase II clinical studies in leukemia acute myeloid.
The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the main market of the Warsaw Stock Exchange and is part of the sWIG80 index. For more information, please see www.ryvu.com.
SOURCE Ryvu Therapeutics
